Volume 9, Number 11—November 2003
Dispatch
Levofloxacin Treatment Failure in Haemophilus influenzae Pneumonia
Table
Strain no. | MIC (µg/mL) |
Amino acid at specified positions |
|||||
---|---|---|---|---|---|---|---|
CIP | LEV | MOXI | GATI | GyrA | ParC | ParE | |
ATCC 51907 | 0.007 | 0.03 | 0.01 | 0.003 | 84 Ser 88 Asp | 84 Ser | 420 Asp |
32602, 35102, 35202 | 16 | 16 | 8 | 16 | Leu Asn | Ile | Asn |
aQRDR, quinolone resistance-determining regions; CIP, ciprofloxacin; LEV, levofloxacin; MOXI, moxifloxacin; GATI, gatifloxacin. Microdilution used for susceptibility testing (8).
References
- Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31–40. DOIPubMedGoogle Scholar
- Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–54.PubMedGoogle Scholar
- Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;49:709–12. DOIPubMedGoogle Scholar
- Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain (1990 to 1996). J Clin Microbiol. 1998;36:3447–54.PubMedGoogle Scholar
- Campos J, Chanyangam M, deGroot R, Smith AL, Tenover FC, Reig R. Genetic relatedness of antibiotic resistance determinants in multiply resistant Haemophilus influenzae. J Infect Dis. 1989;160:810–7. DOIPubMedGoogle Scholar
- Davidson R, Cavalcanti R, Brunton JL, Bast DJ, Azavedo JCS, Kibsey P, Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med. 2002;346:747–50. DOIPubMedGoogle Scholar
- Campos J, Sáez-Nieto JA. Gram negative infections: Haemophilus and other clinically relevant Gram negative coccobacilli. In: Cimolai N, editor. Laboratory diagnosis of bacterial infections. New York: Marcel Dekker, Inc; 2001. p. 557–80.
- Performance standards for antimicrobial susceptibility testing: eleventh informational supplement. Wayne (PA): National Committee for Clinical Laboratory Standards (NCCLS document no. M100–S11); 2001.
- Sánchez L, Pan W, Viñas M, Nikaido H. The acrAB homolog of H. influenzae codes for a functional multidrug efflux pump. J Bacteriol. 1997;179:6855–7.PubMedGoogle Scholar
- Campos J, Román F, Georgiou M, García C, Gómez-Lus R, Cantón R, Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis. 1996;174:1345–7. DOIPubMedGoogle Scholar
- Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995;269:496–512. DOIPubMedGoogle Scholar
- Georgiou M, Muñoz R, Román F, Cantón R, Gómez-Lus R, Campos J, Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC. Antimicrob Agents Chemother. 1996;40:1741–4.PubMedGoogle Scholar
- Pérez-Vázquez M, Camacho T, Román F, Campos J, Cantón R. Mutations in quinolone-resistant determining regions (QRDR) of gyrA, gyrB, parC and parE genes in Haemophilus influenzae clinical isolates. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois; December 16–19, 2001; Abstract 145. Washington: American Society for Microbiology; 2001.
- Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl 3):S147–56. DOIPubMedGoogle Scholar
- Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41:2256–60.PubMedGoogle Scholar
Page created: April 20, 2012
Page updated: April 20, 2012
Page reviewed: April 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.